Prediction of potential drugs and targets based on meibomian gland dysfunction module classification to guide individualized treatment

Abstract

Meibomian gland dysfunction (MGD) is an epidemic chronic ocular inflammation. However, little is known about its effective treatment. Here, this study identified important MGD‐related genes, core regulators, and potential drugs and their targets though integrating a series of bioinformational analyses. First, there were 665 differentially expression genes (DEGs) were identified. Then, 56 coexpression modules were exacted based on the expression of DEGs and their interactors. Moreover, core transcription factors (TF) significantly regulated modules were identified, including RELA, HIF1A, SIRT1, and MYC, which related to variety of eye diseases. Finally, the prediction of potential drugs and the identification of their target were performed. The results showed that artenimol, copper, and glutathione may have the remarkable curative effect or the toxicology to MGD. Moreover, their targets module gene LDHA (lactate dehydrogenase A), ENO1 (enolase 1), ALB (albumin), and PKM (pyruvate kinase M) are play important role in eye diseases. It suggests that these potential drugs may be useful for the treatment of MGD by acting on their targets. It provides valuable references for drug redirection and new drug development for drug developers, and provides individualized treatment strategies for tarsal gland dysfunction.

Proteomic Profiling of Saliva and Tears in Radiated Head and Neck Cancer Patients as Compared to Primary Sjögren’s Syndrome Patients

“…The most highly upregulated protein was mucin-like protein 1. This protein is associated with meibomian gland (MG) dysfunction [ 50 ]. MGs are found in the upper and lower lids of the eyes, and it is not unlikely that these glands were affected by the RT in our study.…”

NGS Analysis Confirms Common TP53 and RB1 Mutations, and Suggests MYC Amplification in Ocular Adnexal Sebaceous Carcinomas

“…They are reported to be more common in the upper lid where there is a higher density of Meibomian glands [23,63]. The histomorphologic features of sebaceous glands from tamoxifen-inducible cMYC mice are well documented, and a few studies have identified MYC as a differentially expressed transcription factor and potential therapeutic target in Meibomian gland dysfunction [64][65][66][67][68][69][70]. However, few studies interrogating MYC expression in normal Meibomian glands have been published.…”